Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation A Secondary Analysis of the AVERROES Study

被引:15
|
作者
Lip, Gregory Y. H. [1 ]
Eikelboom, John [2 ,3 ]
Yusuf, Salim [2 ,3 ]
Shestakovska, Olga [2 ,3 ]
Hart, Robert G. [2 ,3 ]
Connolly, Stuart [2 ,3 ]
机构
[1] Univ Birmingham, City Hosp, Ctr Cardiovas Sci, Birmingham, W Midlands, England
[2] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada
[3] McMaster Univ, Hamilton, ON, Canada
关键词
aspirin; atrial fibrillation; hemorrhage; stroke; STROKE; WARFARIN; TRIALS;
D O I
10.1161/STROKEAHA.114.005746
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The main objective of the present analysis was to assess the effect of treatment with aspirin compared with apixaban on ischemic stroke and major bleeding in women compared with men. Female patients with atrial fibrillation are at increased stroke risk compared with male patients, and the underlying reasons for higher risk are uncertain. Methods-Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences. Mean follow-up was 1.1 years. Results-Women compared with men tended to be older (aspirin, 71.8 versus 68.8 years; apixaban, 71.4 versus 68.6 years), with a higher proportion of those aged >= 75 years. Also, women had less peripheral artery disease (aspirin, 2.4% versus 3.7%; apixaban, 1.4% versus 3.0%), more heart failure, and higher mean CHADS(2) (congestive heart failure, hypertension, age of 75 years or older, diabetes [1 point each], stroke or transient ischemic attack [2 points]) scores (aspirin, 2.2 versus 2.0; apixaban, 2.1 versus 2.0). Women compared with men had higher ischemic stroke rates (aspirin, 3.99% versus 2.28%; apixaban, 1.55% versus 0.82%) but similar bleeding rates (aspirin, 1.29% versus 1.22%; apixaban, 1.15% versus 1.36%). The relative effect of apixaban compared with aspirin was similar in men and women for both ischemic stroke (women, 3.99% versus 1.55%; hazard ratio, 0.39; 95% confidence interval, 0.23-0.64; men, 2.28% versus 0.82%; hazard ratio, 0.36; 95% confidence interval, 0.19-0.63; P-int = 0.84) and major bleeding (women, 1.29% versus 1.15%; hazard ratio, 1.15; 95% confidence interval, 0.59-2.23; men, 1.36% versus 1.22%; hazard ratio, 1.13; 95% confidence interval, 0.64-2.02; P-int = 0.96). Conclusions-Female patients with atrial fibrillation had higher ischemic stroke rates compared with male patients, but the relative effects of apixaban compared with aspirin on both ischemic stroke and bleeding were similar in men and women.
引用
收藏
页码:2127 / 2130
页数:4
相关论文
共 50 条
  • [1] Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS2 and CHA2DS2-VASc Scores in Patients With Atrial Fibrillation A Secondary Analysis of the AVERROES Study
    Lip, Gregory Y. H.
    Connolly, Stuart
    Yusuf, Salim
    Shestakovska, Olga
    Flaker, Greg
    Hart, Robert
    Lanas, Fernando
    Xavier, Denis
    Eikelboom, John
    [J]. CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2013, 6 (01): : 31 - 38
  • [2] Apixaban Versus Aspirin in Atrial Fibrillation Patients ≥ 75 Years Old: an Analysis From the AVERROES Trial
    Ng, K.
    Shestakovska, O. O.
    Eikelboom, J. W.
    Connolly, S. J.
    Yusuf, S.
    Hart, R. G.
    [J]. STROKE, 2013, 44 (12) : E187 - E187
  • [3] Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial
    Eikelboom, J.
    Synhorst, D.
    Wright, R.
    Wang, L.
    Afzal, R.
    Yusuf, S.
    Connolly, S. J.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 465 - 465
  • [4] Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial
    Amin, Alpesh
    Deitelzweig, Steve
    Jing, Yonghua
    Makenbaeva, Dinara
    Wiederkehr, Daniel
    Lin, Jay
    Graham, John
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (03) : 235 - 240
  • [5] Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study
    Lip, Gregory Y.
    Yusuf, Salim
    Eikelboom, John
    Flaker, Greg
    Hart, Robert
    Lanas-Zenetti, Fernando
    Xavier, Denis
    Connolly, Stuart
    [J]. CIRCULATION, 2011, 124 (21)
  • [6] Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
    Vinereanu, Dragos
    Stevens, Susanna R.
    Alexander, John H.
    Al-Khatib, Sana M.
    Avezum, Alvaro
    Bahit, Maria Cecilia
    Granger, Christopher B.
    Lopes, Renato D.
    Halvorsen, Sigrun
    Hanna, Michael
    Husted, Steen
    Hylek, Elaine M.
    Margulescu, Andrei D.
    Wallentin, Lars
    Atar, Dan
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3268 - U77
  • [7] Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
    Diener, Hans-Christoph
    Eikelboom, John
    Connolly, Stuart J.
    Joyner, Campbell D.
    Hart, Robert G.
    Lip, Gregory Y. H.
    O'Donnell, Martin
    Hohnloser, Stefan H.
    Hankey, GraemeJ
    Shestakovska, Olga
    Yusuf, Salim
    [J]. LANCET NEUROLOGY, 2012, 11 (03): : 225 - 231
  • [8] Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
    Benz, Alexander P.
    Eikelboom, John W.
    Yusuf, Salim
    Hohnloser, Stefan H.
    Kahl, Anja
    Beresh, Heather
    Balasubramanian, Kumar
    Healey, Jeff S.
    Connolly, Stuart J.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2021, 121 (04) : 518 - 528
  • [9] Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
    Mavri, Alenka
    Vene, Nina
    Bozic-Mijovski, Mojca
    Miklic, Marko
    Soderblom, Lisbeth
    Pohanka, Anton
    Malmstrom, Rickard E.
    Antovic, Jovan
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [10] Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
    Alenka Mavri
    Nina Vene
    Mojca Božič-Mijovski
    Marko Miklič
    Lisbeth Söderblom
    Anton Pohanka
    Rickard E. Malmström
    Jovan Antovic
    [J]. Scientific Reports, 11